Alnylam Pharmaceuticals (NASDAQ:ALNY) Rating Lowered to “Hold” at StockNews.com

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Several other research analysts have also weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Barclays raised their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Raymond James upped their target price on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. William Blair reiterated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Needham & Company LLC restated a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:ALNY opened at $253.07 on Thursday. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. The business has a fifty day moving average of $271.48 and a two-hundred day moving average of $240.29. The stock has a market cap of $32.64 billion, a P/E ratio of -96.85 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The company’s revenue was down 33.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 EPS. On average, research analysts expect that Alnylam Pharmaceuticals will post -2.21 earnings per share for the current year.

Insider Buying and Selling

In other news, CMO Pushkal Garg sold 1,682 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at approximately $4,381,357.86. This represents a 8.79 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Tolga Tanguler sold 1,469 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,370 shares of company stock worth $2,100,703 over the last 90 days. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Kennedy Capital Management LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter valued at about $231,000. Tidal Investments LLC grew its position in shares of Alnylam Pharmaceuticals by 292.3% during the first quarter. Tidal Investments LLC now owns 10,281 shares of the biopharmaceutical company’s stock worth $1,536,000 after acquiring an additional 7,660 shares during the last quarter. iA Global Asset Management Inc. grew its position in shares of Alnylam Pharmaceuticals by 28.2% during the first quarter. iA Global Asset Management Inc. now owns 7,765 shares of the biopharmaceutical company’s stock worth $1,160,000 after acquiring an additional 1,710 shares during the last quarter. Swedbank AB acquired a new position in shares of Alnylam Pharmaceuticals in the 1st quarter valued at $3,084,000. Finally, Burney Co. raised its position in Alnylam Pharmaceuticals by 371.9% in the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock valued at $4,044,000 after purchasing an additional 21,325 shares during the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.